ENANTA PHARMA - Debut of a Star- 2nd in the Oral IFN free HCV Drug Race!
https://www.reportscorner.com/reports/15825/ENANTA-PHARMA---Debut-of-a-Star--2nd-in-the-Oral-IFN-free-HCV-Drug-Race!/
Gilead entered the HCV race with the acquisition of Pharmasset in 2011 and ABBV through its alliance with Enanta (ENTA) in 2006. Gilead’s Sofosbuvir (PhIII, PMI) in combination with RBV and GS-5885 (PhIII, NS5A inhibitor) is all set to enter the market by 2014 but ENTA/ABBV’s DAAs (ABT-450, PI/r + ABT-333, PMI + ABT-267, NS5AI) will not be too far behind. In PhIIb AVIATOR study, tirade of DAAs demonstrated SVR12 (ITT) of 97.5%, and 93.3% in treatment-naïve pts and null responder HCV GT1 pts respectively. The total INF-free HCV market is expected to grow beyond $10b and as a second entrant ABT-450 combo could achieve…..For more detail, please read our initiation report released on 17th April, 2013 on ENTA titled “Debut of a Star- 2nd in the Oral IFN free HCV Drug Race!
https://www.reportscorner.com/reports/15825/ENANTA-PHARMA---Debut-of-a-Star--2nd-in-the-Oral-IFN-free-HCV-Drug-Race!/
Gilead entered the HCV race with the acquisition of Pharmasset in 2011 and ABBV through its alliance with Enanta (ENTA) in 2006. Gilead’s Sofosbuvir (PhIII, PMI) in combination with RBV and GS-5885 (PhIII, NS5A inhibitor) is all set to enter the market by 2014 but ENTA/ABBV’s DAAs (ABT-450, PI/r + ABT-333, PMI + ABT-267, NS5AI) will not be too far behind. In PhIIb AVIATOR study, tirade of DAAs demonstrated SVR12 (ITT) of 97.5%, and 93.3% in treatment-naïve pts and null responder HCV GT1 pts respectively. The total INF-free HCV market is expected to grow beyond $10b and as a second entrant ABT-450 combo could achieve…..For more detail, please read our initiation report released on 17th April, 2013 on ENTA titled “Debut of a Star- 2nd in the Oral IFN free HCV Drug Race!
No comments:
Post a Comment